Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Comité Científico del Estudio IBERPOC.
Proyecto IBERPOC: un estudio epidemiológico de la EPOC en España.
Arch Bronconeumol, 33 (1997), pp. 293-299
[2.]
J. Manfreda, Y. Mas, W. Litven.
Morbidity and mortality from chronic obstructive pulmonary disease.
Am Rev Respir Dis, 140 (1989), pp. 19-26
[3.]
S. Hurd.
The impact of COPD on lung health world wide. Epidemiology and incidence.
Chest, 117 (2000), pp. 1-4
[4.]
R.A. Pauwels, A.S. Buist, P. Calverley, C.R. Jenkins, S. Hurd.
Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global initiative for chronic obstructive lung disease.
Am J Respir Crit Care Med, 163 (2001), pp. 1256-1276
[5.]
B.R. Celli, W. MacNee.
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.
Eur Respir J, 23 (2004), pp. 932-946
[6.]
J.A. Barberá, G. Peces-Barba, A.G.N. Agustí, J.L. Izquierdo, E. Monsó, T. M.ontemayor, et al.
Guía clínica para el diagnóstico y el tratamiento de la EPOC.
Arch Bronconeumol, 37 (2001), pp. 297-316
[7.]
R.J. Halbert, S. Isonaka, D. George, A. Iqbal.
Interpreting COPD prevalence estimates: what is the true burden of the disease?.
Chest, 123 (2003), pp. 1684-1692
[8.]
D.M. Mannino, D.M. Homa, L.J. Akimbami, E.S. Ford, S.C. Redd.
COPD Surveillance-United States, 1971-2000.
MWMR, 51 (2002), pp. 1-16
[9.]
V. Sobradillo, M. Miravitlles, C.A. Jiménez, R. Gabriel, J.L. Viejo, J.F. Masa, et al.
Estudio IBERPOC en España: prevalencia de síntomas respiratorios habituales y de limitación crónica al flujo aéreo.
Arch Bronconeumol, 35 (1999), pp. 159-166
[10.]
J. Romero, M. Rubio, O. Corral, S. Pacheco, E. Agudo, J.J. Picazo.
Estudio de las infecciones respiratorias extrahospitalarias.
Enf Infec Microbiol Clin, 15 (1997), pp. 289-298
[11.]
Grupo para el estudio de la infección en urgencias.
Sociedad Española de Medicina de Urgencias y Emergencias. Estudio epidemiológicode las infecciones en el área de urgencias.
Emergencias, 12 (2000), pp. 80-89
[12.]
F. Ballester, S. Pérez-Hoyos, M.L. Rivera, T. Merelles, J.M. Tenías, J.B. Soriano, et al.
Patrones de frecuentación y factores asociados al ingreso en el hospitalde las urgencias hospitalarias por asma y por enfermedad pulmonar obstructiva crónica.
Arch Bronconeumol, 35 (1999), pp. 20-26
[13.]
J.F. Masa, V. Sobradillo, C. Villasante, C.A. Jiménez-Ruiz, L. Fernandez-Fau, J.L. Viejo, et al.
Costes de la EPOC en España. Estimación a partir de unestudio epidemiológico poblacional.
Arch Bronconeumol, 40 (2004), pp. 72-79
[14.]
C.J.L. Murray, A.D. Lopez.
Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study.
Lancet, 349 (1997), pp. 1498-1504
[15.]
L. Pezzoli, G. Giardini, S. Consonni, I. Dallera, C. Bilota, G. Ferrario, et al.
Quality of spirometric performance in older people.
Age Ageing, 32 (2003), pp. 43-46
[16.]
G.L. Narsavage, M.D. Naylor.
Factors associated with referral of elderly individuals with cardiac and pulmonary disorders for home care services following hospital discharge.
J Gerontol Nurs, 26 (2000), pp. 14-20
[17.]
A.M. Yohannes, J. Roomi, K. Waters, M.J. Connolly.
Quality of life in elderly patients with COPD : measurement and predictive factors.
Respir Med, 92 (1998), pp. 1231-1236
[18.]
R. Pistelli, P. Lange, D.L. Miller.
Determinants of prognosis of COPD in the elderly: mucus, hipersecretion, infections, cardiovascular comorbidity.
EurRespir J, 40 (2003), pp. 10-14
[19.]
S. Peruzza, G. Sergi, A. Vianello, C. Pisent, F. Tiozzo, A. Manzan, et al.
Chronic obstructive pulmonary disease (COPD) in elderly subjects: impact on functional status and quality of life.
Respir Med, 97 (2003), pp. 612-617
[20.]
A.M. Yohannes, C.C. Hardy.
Treatment of chronic obstructive pulmonary disease in older patients: a practical guide.
Drugs Aging, 20 (2003), pp. 209-228
[21.]
H. Kessel.
La edad como criterio.
Med Clin (Barc), 110 (1998), pp. 736-739
[22.]
R. Zalacain, A. Torres.
Pneumonia in the elderly.
Clin Pulm Med, 11 (2004), pp. 210-218
[23.]
R. Riquelme, A. Torres, M. El-Ebiary, J. Puig de la Bellacasa, R. Estruch, J. Mensa, et al.
Community-acquired penumonia in the elderly. A multivariate analysis of risk and prognostic factors.
Am J Respir Crit. Care Med, 154 (1996), pp. 1450-1455
[24.]
M.S. Houston, M.D. Silverstein, V.J. Suman.
Risk factors for 30-day mortality in elderly patients with lower respiratory tract infection.
Arch Intern Med, 157 (1997), pp. 2190-2195
[25.]
R. Zalacain, A. Torres, R. Celis, J. Blanquer, J. Aspa, L. Esteban, et al.
Community-acquired pneumonia in the elderly: Spanish multicentre study.
Eur Respir J, 21 (2003), pp. 294-302
[26.]
V. Kaplan, D.C. Angus, M. Griffin, G. Clermont, R.S. Watson, W.T. Linde-Zwirble.
Hospitalized community-acquired pneumonia in the elderly. Age and sex related patterns of care and outcome in the United States.
Am J Respir Crit Care Med, 165 (2002), pp. 766-772
[27.]
N. Fernández-Sabé, J. Carratalá, B. Rosón, J. Dorca, R. Verdaguer, F. Manresa, et al.
Community-acquired pneumonia in very elderly patients. Causative organisms, clinical characteristics and outcomes.
Medicine, 82 (2003), pp. 159-169
[28.]
A.A. El-Solh, P. Sikka, F. Ramadan, J. Davies.
Etiology of severe pneumonia in the very elderly.
Am J Respir Crit Care Med, 163 (2001), pp. 645-651
[29.]
E. Martínez-Moragón, L. García, B. Serra, E. Fernández, A. Gómez, R. Julve.
La neumonía adquirida en la comunidad en ancianos: diferencias entrel os que viven en residencias y en domicilios particulares.
Arch Bronconeumol, 40 (2004), pp. 547-552
[30.]
A.A. El-Solh, C. Pietrantoni, A. Bhat, A.T. Aquilina, M. Okada, V. Grover, et al.
Microbiology of severe aspiration pneumonia in institutionalized elderly.
Am J Respir Crit Care Med, 167 (2003), pp. 1650-1654
[31.]
R. Rodríguez-Roisín.
Toward a consensus definition for COPD exacerbations.
Chest, 117 (2000), pp. 398S-401S
[32.]
M. Miravitlles, T. Guerrero, C. Mayordomo, L. Sánchez-Agudo, F. Nicolau, J.L. Segú, on behalf of the EOLO group.
Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis.
Respiration, 67 (2000), pp. 495-501
[33.]
J. Eller, A. Ede, T. Schaberg, M.S. Niederman, H. Mauch, H. Lode.
Infective exacerbations of chronic bronchitis. Relation between bacteriologic etiology and lung function.
Chest, 113 (1998), pp. 1542-1548
[34.]
M. Miravitlles, C. Espinosa, E. Fernández-Laso, J.A. Martos, J.A. Maldonado, M. Gallego.
Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD.
Chest, 116 (1999), pp. 40-46
[35.]
Grupo de trabajo de la Asociación Latinoamericana del Tórax.
Actualizaciónde las recomendaciones ALAT sobre la exacerbación infecciosa de la EPOC.
Arch Bronconeumol, 40 (2004), pp. 315-325
[36.]
S. Saint, S. Bent, E. Vittinghoff, D. Grady.
Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis.
JAMA, 273 (1995), pp. 957-960
[37.]
N.R. Anthonisen, J. Manfreda, C.P. Warren, E.S. Hershfield, G.K. Harding, N.A. Nelson.
Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.
Ann Intern Med, 106 (1987), pp. 196-204
[38.]
R.A. Stockley, C. O’Brien, A. Pye, S.L. Hill.
Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD.
Chest, 117 (2000), pp. 1638-1645
[39.]
Soler N. Agustí C. Angrill J. Puig de la Bellacasa J. Torres A. The significance of sputum purulence in severe exacerbations of Chronic Obstructive Pulmonary Disease: a bronchoscopic study. Thorax. [En prensa]. On line: www.thorax.bmjjournals.com/
[40.]
A.T. Evans, S. Husain, L. Durairaj, L.S. Sadowski, M. Charles-Damte, Y. Wang.
Azithromyc in for acute bronchitis: a randomised, double-blind, controlled trial.
Lancet, 359 (2002), pp. 1648-1654
[41.]
S. Nouira, S. Marghli, M. Belghith, L. Besbes, S. Elatrous, F. Abroug.
Oncedaily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial.
Lancet, 358 (2001), pp. 2020-2025
[42.]
J.L. Álvarez-Sala, E. Cimas, J.F. Masa, M. Miravitlles, J. Molina, K. Naberan, et al.
Recomendaciones para la atención al paciente con enfermedad pulmonary obstructiva crónica.
Arch Bronconeumol, 37 (2001), pp. 269-278
[43.]
F. Álvarez, E. Bouza, J.A. García-Rodríguez, J. Mensa, J. Monsó, J.J. Picazo, et al.
Segundo documento de consenso sobre uso de antimicrobianos en la exacerbación de la enfermedad pulmonar obstructiva crónica.
Arch Bronconeumol, 39 (2003), pp. 274-282
[44.]
V. Sobradillo, M. Miravitlles, R. Gabriel, et al.
Geographic variations inprevalence and underdiagnosis of COPD. Results of the IBERPOC Multicentre Epidemiological Study.
Chest, 118 (2000), pp. 981-989
[45.]
K.H. Groenewegen, E.F. Wouters.
Bacterial infections in patients requeringad mission for an acute exacerbation of COPD; a 1-year prospective study.
Respir Med, 97 (2003), pp. 770-777
[46.]
F. Álvarez, E. Bouza, J.A. García-Rodríguez, M.A. Mayer, J. Mensa, E. Monso, et al.
Uso de antimicrobianos en la exacerbación de la enfermedad pulmonary obstructiva crónica.
Aten Primaria, 28 (2001), pp. 415-424
[47.]
E. Monsó.
Colonización bronquial en la enfermedad pulmonar obstructiva crónica: algo se esconde debajo de la alfombra.
Arch Bronconeumol, 40 (2004), pp. 543-546
[48.]
E. García-Vázquez, M.A. Marcos, J. Mensa, A. De Roux, J. Puig, C. Font, et al.
Assessment of the Usefulness of Sputum Culture for Diagnosis of Community-Acquired Pneumonia Using the PORT Predictive Scoring System.
Arch Intern Med, 164 (2004), pp. 1807-1811
[49.]
P. Ball, J.M. Harris, D. Lowson, et al.
Acute infective exacerbation of chronic bronchitis.
QJM, 88 (1995), pp. 61-68
[50.]
C.A. DeAbate, D. Henry, G. Bensch, A. Jubran, S. Chodosh, L. Harper, et al.
Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study Sparfloxacin Multicenter ABECB Study Group.
Chest, 114 (1998), pp. 120-130
[51.]
A. Anzueto, M.S. Niederman, G.S. Tillotson.
Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitisin the primary care setting: ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d. Bronchitis Study Group.
Clin Ther, 20 (1998), pp. 885-900
[52.]
E. Monso, J. Ruiz, A. Rosell, J. Manterola, J. Fiz, J. Morera, et al.
Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brusch.
Am J Respir Crit Care Med, 152 (1995), pp. 1316-1320
[53.]
P. Ball, B. Make.
Acute exacerbations of chronic bronchitis: an international comparison.
Chest, 113 (1998), pp. 199-204
[54.]
T.M. File Jr, M.R. Jacobs, M.D. Poole, B. Wynne.
Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate.
Int J Antimicrob Agents, 20 (2002), pp. 235-247
[55.]
Normativas para el diagnóstico y el tratamiento de la neumonía adquirida en la comunidad Sociedad Española de Neumología y Cirugía Torácica(SEPAR).
Arch Bronconeumol, 41 (2005), pp. 272-289
[56.]
S.G. Adams, J. Melo, M. Luther, A. Anzueto.
Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD.
Chest, 117 (2000), pp. 1345
[57.]
M.I. Morosini, R. Canton, E. Loza, M.C. Negri, J.C. Galan, F. Almaraz, et al.
In vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance mechanisms.
Antimicrob Agents Chemother, 45 (2001), pp. 2427-2431
[58.]
O. Kucukbasmaci, N. Gonullu, Z. Aktas, G.D. Berkiten.
In vitro activity of telithromycin compared with macrolides and fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
J Antimicrob Agents, 22 (2003), pp. 497-501
[59.]
M. Aubier, P.M. Aldons, A. Leak, D.D. McKeith, B. Leroy, M. Rangaraju, et al.
Telithromycin is as effective as amoxicillin/ clavulanate in acute exacerbations of chronic bronchitis.
Respir Med, 96 (2002), pp. 862-871
[60.]
J.M. Blondeau, G.S. Tillotson.
Antimicrobial susceptibility patterns of respiratory pathogens-a global perspective.
Semin Respir Infect, 15 (2000), pp. 195-207
[61.]
R. Wilson, R. Kubin, I. Ballin, K.M. Deppermann, H.P. Bassaris, P. Leophonte, et al.
Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.
JAntimicrob Chemother, 44 (1999), pp. 501-513
[62.]
J. Lorenz, I.M. Thate-Waschke, O. Mast, R. Kubin, R. Rychlik, T. Pfeil, et al.
Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective.
J Int Med Res, 29 (2001), pp. 74-86
[63.]
P.M. Shah, F.P. Maesen, A. Dolmann, N. Vetter, E. Fiss, R. Wesch.
Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronicbronchitis: results of a randomized, double-blind study.
J Antimicrob Chemother, 43 (1999), pp. 529-539
[64.]
J. Garcia-De-Lomas, C. Garcia-Rey, L. Lopez, C. Gimeno.
Susceptibility patterns of bacteria causing community-acquired respiratory infections in Spain: the SAUCE project.
J Antimicrob Chemother, 50 (2002), pp. 21-26
[65.]
J.A. Garcia, F. Baquero, J. Garcia, et al.
Anti microbial susceptibility of 1.422 Haemophilus influenzae isolates from respiratory tract infections in Spain: results of a 1-year. (1996-97) multicenter sueveillance study: Spanish Surveillance Group for Respiratory Pathogens.
Infection, 27 (1999), pp. 265-267
[66.]
K.H. Gronewegen, A.M.W.J. Schol, E.F.M. Wouters.
Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD.
Chest, 124 (2003), pp. 459-467
[67.]
R.A. Incalzi, L. Fuso, M. De Rosa, F. Forastiere, E. Rapiti, B. Nardecchia, et al.
Comorbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease.
Eur Respir J, 10 (1997), pp. 2794-2800
[68.]
A. Anzueto, S. Norris.
Clarithromycin in 2003: sustained efficacy and safety in an era of rising antibiotic resistance.
Int J Antimicrob Agents, 24 (2004), pp. 1-17
[69.]
H. Lode, J. Eller, A. Linnhoff, M. Ioanas, Evaluation of therapy-free intervalin COPD Patients Study Group.
Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval.
Eur Respir J, 24 (2004), pp. 947-953
[70.]
M.H. Gotfried.
Comparison of bacteriologic eradication of Streptococcus pneumoniae by clarithromycin and reports of increased antimicrobial resistance.
Clin Ther, 22 (2000), pp. 2-14
[71.]
M.H. Gotfried.
Macrolides for the treatment of chronic sinusitis, asthma, and COPD.
Chest, 125 (2004), pp. 52-60
[72.]
D.R. Guay.
Review of cefditor en, an advanced-generation, broad-spectrum oral cephalosporin.
Clin Ther, 23 (2001), pp. 1924-1937
[73.]
C.L. Clark, K. Nagay, B.E. Dewasse, G.A. Pankuch, L.M. Ednie, M.R. Jacobs, et al.
Activity of cefditoren against respiratory pathogens.
J Antimicrob Chemother, 50 (2002), pp. 33-41
[74.]
N. Soler, A. Torres, S. Ewig, J. Gonzalez, R. Celis, M. El-Ebiary, et al.
Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease. (COPD) requiring mechanical ventilation.
Am J Respir Crit Care Med, 157 (1998), pp. 1498-1505
[75.]
J.Y. Fagon, J. Chastre, J.L. Trouillet, Y. Domart, M.C. Dombret, et al.
Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients.
Am Rev Respir Dis, 142 (1990), pp. 1004-1008
[76.]
E. Monso, J. Garcia-Aymerich, N. Soler, E. Farrero, M.A. Felez, J.M. Anto, et al.
EFRAM Investigators. Bacterial infection in exacerbated COPD with changes in sputum characteristics.
Epidemiol Infect, 131 (2003), pp. 799-804
[77.]
M.S. Balter, J. La Forge, D.E. Low, et al.
Canadian guidelines for the management of acute exacerbations of chronic bronchitis.
Can Respir J, 10 (2003), pp. 3B-32B
[78.]
R. Wilson, L. Allegra, G. Huchon, J.L. Izquierdo, P. Jones, T. Schaberg, MOSAIC Study Group, et al.
Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis.
Chest, 125 (2004), pp. 953-964
[79.]
R.F. Grossman.
Cost-effective therapy for acute exacerbations of chronicbronchitis.
Semin Respir Infect, 15 (2000), pp. 71-81
[80.]
M. Miravitlles.
Treatment failure of acute exacerbations of chronic obstructive airways disease risk factors and clinical relevance.
Med Clin (Barc), 119 (2002), pp. 304-314
[81.]
N.A. Dewan, S. Rafique, B. Kanwar, H. Satpathy, K. Ryschon, G.S. Tillotson, et al.
Acute exacerbation of COPD: factors associated with poor treatment outcome.
Chest, 117 (2000), pp. 662-671
[82.]
E. Loza, E. Loza, J. Liñares, R. Cantón, A. Pascual, M.I. Morosini, et al.
Programa SENTRY (España) 1999-2000.
Enf Inf Microbiol Clin, 21 (2003), pp. 404-409
[83.]
E. Bouza, F. García-Garrote, E. Cercenado, M. Marín, M.S. Díaz, I. SánchezRomero, et al.
Grupo Español para el estudio de Pseudomonas aeruginosa. Pseudomonas aeruginosa: a multicenter study in 136 hospitals in Spain.
Rev Esp Quimioter, 16 (2003), pp. 41-52
[84.]
E. Boselli, D. Breilh, T. Rimmele, et al.
Pharmakokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia.
Crit Care Med, 33 (2005), pp. 104-109
[85.]
FDA. Ficha técnica de Levaquin IV de 500 y 750 mg.
[86.]
FDA. Ficha técnica de Cipro IV.
[87.]
Guidelines for the management of adults with hospital acquired, ventilator associated and healthcare associated pneumonia. Am J Resp Crit Care Med. 2005;171:388-416.
[88.]
S. Chodosh, C.A. DeAbate, D. Haverstock, et al.
Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis.
Respir Med, 94 (2000), pp. 18-27
[89.]
R.G. Masterton, C.J. Burley.
Randomized, double-blind study comparing5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis.
Int J Antimicrob Agents, 18 (2001), pp. 503-512
[90.]
Ficha técnica de Amoxicilina-Ácico clavulánico, Azitromicina, Cefepima, Cefotaxima, Ceftriaxona, Ciprofloxacino, Claritromicina, Levofloxacino, Moxifloxacino y Telitromicina.
[91.]
R. Finch, D. Schurmann, O. Collins, R. Kubin, J. McGivern, H. Bobbaers, et al.
Randomized controlled trial of sequential intravenous (iv) and oral moxifloxacin compared with sequential iv and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
Antimicrob Agents Chemother, 46 (2002), pp. 1746-1754
[92.]
A. Heyd, D. Haverstock.
Retrospective analysis of the safety profile of oral and intravenous ciprofloxacin in a geriatric population.
Clin Ther, 22 (2000), pp. 1239-1250
[93.]
V.T. Andriole, D.C. Haverstock, S.H. Choudhri.
Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinicaltrials.
Drug Saf, 28 (2005), pp. 443-452
[94.]
E. Vargas Castrillón, V. De Miguel Gallo, A. Moreno González.
Los fármacoscomo factor de riesgo en el anciano.
Factores de riesgo en la patología geriátrica, pp. 235-245
[95.]
A. Orero, J. González, J. Prieto, Por el Grupo de Estudio del Uso Racionalde los Antibióticos Orales (URANO).
Antibióticos en los hogares españoles. Implicaciones médicas y socioeconómicas.
Med Clin (Barc), 109 (1997), pp. 782-785
[96.]
Grupo de trabajo sobre incumplimiento.
Incumplimiento terapéutico en los ancianos.
Med Clin (Barc), 100 (1993), pp. 736-740
[97.]
J. Romero Vivas, M. Rubio Alonso, O. Corral, S. Pacheco, E. Agudo, J.J. Picazo.
Estudio de las infecciones respiratorias extra hospitalarias.
Enferm Infecc Microbiol Clin, 15 (1997), pp. 289-298
[98.]
M.A. Ripio, A. Orero, J. González, Por el Grupo Urano.
Prescripción de antibióticosen Atención Primaria en España. Motivos y características.
MedicinaGeneral, 48 (2002), pp. 785-790
[99.]
F. Baquero, J.A. García-Rodríguez, J. García de Lomas, L. Aguilar, Spanish Surveillance Group for Respiratory Pathogens.
Antimicrobial resistance of 1.113 Streptococcus pneumoniae isolates from respiratory tract infections in Spain. Results of one-year (1996-97) multicenter surveillance study. Antimicrob.
Agents Chemother, 43 (1999), pp. 357-359
[100.]
M.A. Ripio, A. Orero, J. Prieto.
Resistencias bacterianas. Opinión de los medicos de Atención Primaria españoles.
Medicina General, 25 (2000), pp. 539-545
[101.]
F. Soriano, J.J. Granizo, A. Fenoll, M. Gracia, R. Fernandez-Roblas, J. Esteban, et al.
Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four southern European countries (ARISE project) from adult patients: results from the cefditor en surveillance program.
J Chemother, 15 (2003), pp. 107-112
[102.]
J. García-de-Lomas, L. López Cerezo, C. Gimeno Cardona.
y Grupo Españolpara la Vigilancia de los Patógenos Respiratorios (GEVIPAR) Sensibilidad de los patógenos respiratorios en la comunidad en España: resultados del estudio Sauce.
An Esp Pediatr, 56 (2002), pp. 9-19
[103.]
Antimicrobianos en medicina,
[104.]
M. Miravitlles.
Fracaso en el tratamiento de las agudizaciones de la enfermedad pulmonar obstructiva crónica. Factores de riesgo e importancia clínica.
Med Clin (Barc), 119 (2001), pp. 304-314
[105.]
M. Miravitlles, C. Murio, T. Guerrero, On behalf of the DAFNE study group. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis.
A prospective multicenter study in the community.
Eur Respir J, 17 (2001), pp. 928-933
[106.]
A.F. Connors, N.V. Dawson, C. Thomas, F.E. Harrel, N. Desbiens, W.J. Fulkerson, et al.
Outcomes following acute exacerbation of severe chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 154 (1996), pp. 959-967
[107.]
T.A. Seemungal, G.C. Donaldson, A. Bhowmik, D.J. Jeffries, J.A. Wedzocha.
Effectof exacerbation on quality of life in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 157 (1998), pp. 1418-1422
[108.]
D.E. Niewoehner, M.L. Erbland, R.H. Deupree, D. Collins, N.J. Gross, R.L. Light, et al.
Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease.
N Engl J Med, 340 (1999), pp. 1941-1947
[109.]
L. Davies, R.M. Angus, P.M.A. Calverley.
Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial.
Lancet, 354 (1999), pp. 456-460
[110.]
D.E. Niewoehner.
Interventions to prevent chronic obstructive pulmonary disease exacerbations.
Am J Med, 117 (2004), pp. 41S-48S
[111.]
T. Staykova, P. Black, E. Chacko, F.S.F. Ram, P. Poole.
Prophylactic antibiotic therapy for chronic bronchitis (Cochrane Review).
The Cochrane Library, Issue 4, John Wiley & Sons, (2004),
[112.]
P.J. Poole, P.N. Black.
Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review.
BMJ, 322 (2001), pp. 1271-1274
[113.]
M. Decramer, M. Rutten-van Molken, P.N. Dekhuijzen, T. Troosters, C. Van Herwaarden, R. Pellegrino, et al.
Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.
Lancet, 365 (2005), pp. 1552-1560
[114.]
P. Calverley, R. Pauwels, J. Vestbo, P. Jones, N. Pride, A. Gulsvik, The TRISTAN (Trial of Inhaled Steroids And long-acting b2 agonists) study group, et al.
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
Lancet, 361 (2003), pp. 449-456
[115.]
J.B. Soriano, J. Vestbo, N.B. Pride, V. Kiri, C. Maden, W.C. Maier.
Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice.
Eur Respir J, 20 (2002), pp. 819-825
[116.]
J. Vestbo, TORCH Study Group.
The TORCH (towards a revolution in COPD health) survival study protocol.
Eur Respir J, 24 (2004), pp. 206-210
[117.]
R. Hubbard, A. Tattersfield.
Inhaled Corticosteroids, Bone Mineral Density and Fracture in Older People.
Drugs Aging, 21 (2004), pp. 631-638
[118.]
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [Actualización 2004]. Disponible en: http://www.goldcopd.com
[119.]
K.L. Nichol, L. Baken, A. Nelson.
Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease.
Ann Intern Med, 130 (1999), pp. 397-403
[120.]
C.H.L. Howells, L.E. Tyler.
Prophylactic use of influenza vaccine in patients with chronic bronchitis.
Lancet, 2 (1961), pp. 1428-1432
[121.]
P. Wongsurakiat, K.N. Maranetra, C. Wasi, U. Kositanont, W. Dejsomritrutai, S. Charoenratanakul.
Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination.
Chest, 125 (2004), pp. 2011-2020
[122.]
K.L. Nichol, L. Baken, J. Wuorenma, A. Nelson.
The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease.
Arch Intern Med, 159 (1999), pp. 2437-2442
[123.]
J.I. Couser, R. Guthmann, M.A. Amadeh, C.S. Kane.
Pulmonary rehabilitacion improves excercise capacity in older elderly patients with COPD.
Chest, 107 (1995), pp. 730-734
[124.]
T.L. Griffiths, M.L. Burr, I.A. Campbell, et al.
Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial.
Lancet, 355 (2000), pp. 362-368
[125.]
A.L. Ries, R.M. Kaplan, R. Myers, L.M. Prewitt.
Maintenance after pulmonary rehabilitation in chronic lung disease: a randomized trial.
Am J Respir Crit Care Med, 167 (2003), pp. 880-888
[126.]
J. Bourbeau, M. Julien, F. Maltais, et al.
Reduction of hospital utilization inpatients with chronic obstructive pulmonary disease: a disease-specific self-management intervention.
Arch Intern Med, 163 (2003), pp. 585-591
[127.]
N.R. Anthonisen, J.E. Connett, J.P. Kiley, M.D. Altose, W.C. Bailey, A.S. Buist, et al.
Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study.
JAMA, 272 (1994), pp. 1497-1505
[128.]
E.J. Wagena, R.B. Van der Meer, R.J. Ostelo, J.E. Jacobs, C.P. Van Schayck.
Theefficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review.
Respiratory Medicine, 98 (2004), pp. 805-815
[129.]
O. Gluck, G. Colice.
Recognizing and treating glucocorticoid-induced osteoporosis in patients with pulmonary diseases.
Chest, 125 (2004), pp. 1859-1876
[130.]
C.E. McEvoy, K.E. Ensrud, E. Bender, et al.
Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonarydisease.
Am J Respir Crit Care Med, 157 (1998), pp. 704-709
[131.]
A. Alsaeedi, D.D. Sin, F.A. McAlister.
The effects of inhaled corticosteroids inchronic obstructive pulmonary disease: a systematic review of randomizedplacebo-controlled trials.
Am J Med, 113 (2002), pp. 59-65
[132.]
R.B. Hubbard, C.J. Smith, L. Smeeth, T.W. Harrison, A.E. Tattersfield.
Inhaledcorticosteroids and hip fracture: a population-based case-control study.
Am J Respir Crit Care Med, 166 (2002), pp. 1563-1566
[133.]
R.G. Cumming, P. Mitchell, S.R. Leeder.
Use of inhaled corticosteroids and the risk of cataracts.
N Engl J Med, 337 (1997), pp. 8-14
[134.]
E. Garbe, J. LeLorier, J.F. Boivin, S. Suissa.
Risk of ocular hypertension orop en-angle glaucoma in elderly patients on oral glucocorticoids.
Lancet, 350 (1997), pp. 979-982
[135.]
F.S.F. Ram, J.A. Wedzicha, J. Wright, M. Greenstone.
Hospital at home foracute exacerbations of chronic obstructive pulmonary disease (Cochrane Review).
The Cochrane Library, Issue 2, John Wiley & Sons, (2004),
[136.]
S. Shepperd, D. Harwood, A. Gray, M. Vessey, P. Morgan.
Randomised controlled trial comparing hospital at home care with inpatient hospital care. II: cost minimisation analysis.
BMJ, 316 (1998), pp. 1791-1799
[137.]
J. Jones, A. Wilson, H. Parker, A. Wynn, C. Jagger, N. Spiers, et al.
Economic evaluation of hospital at home versus hospital care: cost minimisation analysis of data from randomised controlled trial.
BMJ, 319 (1999), pp. 1547-1550
De acuerdo con los autores y los editores, este artículo se publica paralelamente y de forma íntegra en las siguientes publicaciones: Semergen, REVISTA ESPAÑOLA DE GERIATRÍA Y GERONTOLOGÍA y aparecerá en el volumen 42, Extraordinario 3 de 2006 de la Revista Archivos de Bronconeumología.
Copyright © 2006. Sociedad Española de Geriatría y Gerontología
